卫生技术评估生命周期概念：药物报销不确定性政策演变范围综述
Health Technology Assessment Lifecycle Concepts: A Scoping Review Outlining the Change in Policies to Manage Uncertainties Associated With Reimbursement of Medicines
作者：Jelle Stoelinga、Carla E. Hollak、Lonneke Timmers、Wim Goettsch、Christine Leopold
单位：Division of Pharmacoepidemiology and Clinical Pharmacy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.；RARE-NL, foundation supporting academic medicines development and access, Amsterdam, the Netherlands; Department of Endocrinology and Metabolism, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.；National Health Care Institute (Zorginstituut Nederland, ZIN), Diemen, the Netherlands; Erasmus School of Health Policy and Management, Rotterdam, the Netherlands.；Division of Pharmacoepidemiology and Clinical Pharmacy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands; National Health Care Institute (Zorginstituut Nederland, ZIN), Diemen, the Netherlands.；Division of Pharmacoepidemiology and Clinical Pharmacy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands. Electronic address: c.leopold@uu.nl.
摘要
本文发表于Value in Health（ISPOR官方期刊），由Stoelinga等人撰写，系统梳理了卫生技术评估（HTA）在药物报销决策中的生命周期框架及政策演变。研究聚焦于管理报销不确定性的政策工具创新，涵盖条件性报销、分期支付、风险分担机制等，适用于关注药物市场准入策略的读者参考。
AI 主编 · 推荐理由推荐理由
我国HTA制度正在完善阶段，该文系统梳理国际经验，对药企制定中国市场准入策略、应对医保谈判不确定性具有参考价值，可借鉴风险分担与条件性报销机制设计。